The Food and Drug Administration recently approved Eli Lilly’s obesity drug Zepbound, also known as tirzepatide, as the first treatment for obstructive sleep apnea (OSA) in the United States. This approval marks a significant milestone as it is the first time Zepbound has been cleared for a condition other than weight loss.
Obstructive sleep apnea is a common sleep disorder characterized by breathing interruptions during sleep. It can have serious health consequences if left untreated, including increased risk of heart disease, stroke, and other complications. Patients with both obesity and moderate-to-severe OSA can now benefit from Zepbound as a targeted treatment option.
The approval of Zepbound for OSA could lead to broader insurance coverage, making it more accessible to patients in need. This development highlights the potential of repurposing existing drugs for new indications, expanding their utility and impact in healthcare.
For more in-depth coverage and analysis of the biotech sector, subscribers can access exclusive articles like this one through STAT+. Subscribing to STAT+ unlocks a wealth of valuable content and insights that can inform decision-making and drive innovation in the industry.
To learn more about Zepbound’s approval for OSA and other breaking news in the biotech sector, consider subscribing to STAT+ today. Stay informed and stay ahead with STAT+.
